Free Trial
NASDAQ:OTLK

Oncobiologics (OTLK) Stock Price, News & Analysis

Oncobiologics logo
$0.99 +0.02 (+1.78%)
Closing price 09/24/2025 04:00 PM Eastern
Extended Trading
$0.98 0.00 (-0.35%)
As of 06:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oncobiologics Stock (NASDAQ:OTLK)

Advanced

Key Stats

Today's Range
$0.97
$1.00
50-Day Range
$0.85
$2.97
52-Week Range
$0.79
$6.98
Volume
848,273 shs
Average Volume
7.03 million shs
Market Capitalization
$43.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Consensus Rating
Hold

Company Overview

Oncobiologics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
44th Percentile Overall Score

OTLK MarketRank™: 

Oncobiologics scored higher than 44% of companies evaluated by MarketBeat, and ranked 670th out of 951 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncobiologics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    Oncobiologics has a consensus price target of $7.00, representing about 608.1% upside from its current price of $0.99.

  • Amount of Analyst Coverage

    Oncobiologics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Oncobiologics' stock forecast and price target.
  • Earnings Growth

    Earnings for Oncobiologics are expected to grow in the coming year, from ($2.27) to ($0.20) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncobiologics is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncobiologics is -1.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    24.08% of the float of Oncobiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncobiologics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncobiologics has recently increased by 133.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Oncobiologics does not currently pay a dividend.

  • Dividend Growth

    Oncobiologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.08% of the float of Oncobiologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Oncobiologics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Oncobiologics has recently increased by 133.22%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Oncobiologics has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Oncobiologics this week, compared to 2 articles on an average week.
  • Search Interest

    49 people have searched for OTLK on MarketBeat in the last 30 days. This is an increase of 158% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Oncobiologics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncobiologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Oncobiologics is held by insiders.

  • Percentage Held by Institutions

    Only 11.20% of the stock of Oncobiologics is held by institutions.

  • Read more about Oncobiologics' insider trading history.
Receive OTLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncobiologics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

OTLK Stock News Headlines

10 Cheap Stocks Ready to Explode
Remember when Nvidia was trading at $60? Yeah, me too. Painful, right? While early investors turned every $10,000 into $100,000+, most of us watched from the sidelines, thinking we'd already missed the boat. Here's the thing though... The AI revolution isn't over. It's just getting started.tc pixel
Outlook Therapeutics Requests Type A Meeting with FDA
See More Headlines

OTLK Stock Analysis - Frequently Asked Questions

Oncobiologics' stock was trading at $1.89 on January 1st, 2025. Since then, OTLK stock has decreased by 47.7% and is now trading at $0.9885.

Oncobiologics, Inc. (NASDAQ:OTLK) announced its earnings results on Thursday, August, 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by $0.02. The company had revenue of $1.51 million for the quarter, compared to the consensus estimate of $1.66 million.

Oncobiologics shares reverse split before market open on Thursday, March 14th 2024.The 1-20 reverse split was announced on Thursday, March 14th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Oncobiologics' top institutional shareholders include Russell Investments Group Ltd. (0.07%) and Group One Trading LLC. Insiders that own company stock include Jeff Evanson, Terry Dagnon, Kurt J Hilzinger, Lawrence A Kenyon and Yezan Munther Haddadin.
View institutional ownership trends
.

Shares of OTLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncobiologics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Intel (INTC) and Sorrento Therapeutics (SRNE).

Company Calendar

Last Earnings
8/14/2025
Today
9/25/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OTLK
CIK
1649989
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$3.00
Potential Upside/Downside
+608.1%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.57)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$75.37 million
Net Margins
N/A
Pretax Margin
-2,886.25%
Return on Equity
N/A
Return on Assets
-332.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.67
Quick Ratio
0.54

Sales & Book Value

Annual Sales
$1.51 million
Price / Sales
29.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.09) per share
Price / Book
-0.32

Miscellaneous

Outstanding Shares
44,420,000
Free Float
42,288,000
Market Cap
$43.91 million
Optionable
Optionable
Beta
0.48

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:OTLK) was last updated on 9/25/2025 by MarketBeat.com Staff
From Our Partners